Molecular rearrangements and morphology in thyroid cancer

American Journal of Pathology

Volumn 160, Issue 6, 2002, Pages 1941-1944

  Kroll, Todd G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGENESIS; CHROMOSOME REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; MORPHOLOGY; NONHUMAN; NOTE; ONCOGENE RET; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CANCER; THYROID PAPILLARY CARCINOMA;

EID: 0036087007     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)61142-X     Document Type: Note

References (50)

1. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases
2. Ptc is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas
3. Pax8-Ppargamma1 fusion oncogene in human thyroid carcinoma
4. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the Ret/Ptc1 oncogene in transgenic mice
5. Sti571: A paradigm of new agents for cancer therapeutics
6. Perspectives on the development of a molecularly targeted agent
7. The theory of Apl
8. Targeted expression of the Ret/Ptc1 oncogene induces papillary thyroid carcinomas
9. Tissue-specific carcinogenesis in transgenic mice expressing the Ret proto-oncogene with a multiple endocrine neoplasia type 2a mutation
10. Development of medullary thyroid carcinoma in transgenic mice expressing the Ret protooncogene altered by a multiple endocrine neoplasia type 2a mutation
11. Mutations in the Ret proto-oncogene are associated with Men 2a and Fmtc
12. Germ-line mutations of the Ret proto-oncogene in multiple endocrine neoplasia type 2a
13. Mutations of the Ret proto-oncogene in the multiple endocrine neoplasia type 2 syndromes and Hirschsprung disease
14. Two critical hits for promyelocytic leukemia
15. A Bcr-3 isoform of Raralpha-Pml potentiates the development of Pml-Raralpha-driven acute promyelocytic leukemia
16. Reversibility of acute B-cell leukaemia induced by Bcr-Abl1
17. The role of Pml in tumor suppression
18. Alterations of the Aml1 transcription factor in human leukemia
19. Aml-1/Eto fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein
20. Aml1-Eto expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations
21. Expression of a conditional Aml-Eto oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia
22. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: A search for the early precursors of papillary cancer
23. Enrichment of epithelial cells for molecular studies
24. Microdis section is essential for gene expression profiling of clinically resected cancer tissues
25. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
26. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia
27. MII translocations specify a distinct gene expression profile that distinguishes a unique leukemia
28. Relation of gene expression phenotype to immuno-globulin mutation genotype in B cell chronic lymphocytic leukemia
29. Ret receptor expression in thyroid follicular epithelial cell-derived tumors
30. Expression and alternative splicing of C-Ret RNA in papillary thyroid carcinomas
31. Expression of the Ret proto-oncogene in papillary thyroid carcinoma and its correlation with clinical outcome
32. Clonal composition of benign and malignant human thyroid tumors
33. Clonal analysis of solitary follicular nodules in the thyroid
34. Clonal origin of non-medullary thyroid tumours assessed by nonrandom X-chromosome inactivation
35. Polyclonal and monoclonal thyroid nodules coexist within human multinodular goiters
36. Clonality of thyroid nodules in sporadic goiter
37. Clonal analysis of a solitary follicular nodule of the thyroid with the polymerase chain reaction method
38. Ret/Ptc oncogene activation is an early event in thyroid carcinogenesis
39. Ret/Ptc oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes
40. Distinct multiple Ret/Ptc gene rearrangements in multifocal papillary thyroid neoplasia
41. The Ret/Ptc oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions
42. Molecular basis of Hurthle cell papillary thyroid carcinoma
43. Distinct pattern of Ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children
44. High prevalence of Ret/Ptc rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: A strong correlation between Ret/Ptc3 and the solid-follicular variant
45. Potent mitogenicity of the Ret/Ptc3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma
46. Encapsulated follicular variant of papillary thyroid carcinoma with bone metastases
47. Why there is the tendency to "overdiagnose" the follicular variant of papillary thyroid carcinoma
48. Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma
49. Follicular-patterned lesions of the thyroid: The bane of the pathologist
50. The role of the pathologist as tissue refiner and data miner: The impact of functional genomics on the modern pathology laboratory and the critical roles of pathology informatics and bioinformatics